Loading
Cancer cells enter the blood mostly during rest, so a morning blood test may miss them. Sampling and dosing at the right hour may be a free improvement.
Circulating tumour cell shedding in breast cancer patients and mouse models peaks during the rest phase, with several-fold differences between night and day samples. Almost all clinical sampling occurs in clinic hours, and almost all therapy is delivered in clinic hours. If shedding and proliferation are circadian, both assay sensitivity and drug timing are currently set by convenience.
Shares Klaus Pantel, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing.
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA), HR-positive / HER2-negative breast cancer.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
Shares Dormant cells and minimal residual disease, Minimal / molecular residual disease (MRD), MRD / molecular residual disease testing, HR-positive / HER2-negative breast cancer.
Shares Minimal / molecular residual disease (MRD), Circulating tumour DNA (ctDNA), Biomarkers are not validated or standardised, MRD / molecular residual disease testing.